All AbMole products are for research use only, cannot be used for human consumption.
SH-4-54 is a potent STAT inhibitor with KD values of 300 nM and 464 nM for STAT3 and STAT5, respectively. SH-4-54 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations. SH-4-54 exhibites blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibites pSTAT3 in vivo.
 |
Source | Int J Mol Sci (2018). Figure 4. SH-4-54 |
| Method | cell viability assay | |
| Cell Lines | LX-2 and HSC-T6 | |
| Concentrations | 1.5 μM or 0.5 μM | |
| Incubation Time | 48 h | |
| Results | A second STAT3 specific inhibitor, SH-4-54, inhibited LX-2 cell viability in a dose-dependent manner with an IC50 of 0.37 μM. |
| Cell Experiment | |
|---|---|
| Cell lines | BTSC lines 25M, 67EF, 73EF, 84EF and 127EF |
| Preparation method | Dissociating BTSC spheres to single cells with the enzyme Accumax, seeding at 1500 cells/ 96-well and treating with drug or vehicle (DMSO) one day after plating. Repeating cytotoxicity studies independently using BTSC lines 25M, 67EF, 73EF, 84EF and 127EF.Dissociating BTSC spheres to single cells as above and plating in 96 well plates in triplicate at 3000 cells/ 96-well. In both sets of experiments using drugs as serial dilutions within the range of 5 μM to 100 nM in the first set and 25 μM to 10 nM. Assessing cell viability following drug treatment three days later using the alamarBlue assay according to the manufacturer’s instructions. All culture experiments are performed in triplicate with a minimum of three wells per condition |
| Concentrations | ~25 μM |
| Incubation time | 72 hours |
| Animal Experiment | |
|---|---|
| Animal models | NOD-SCID bearing ed with BT73 glioma xenografts |
| Formulation | 10 mg/kg |
| Dosages | Suspended in 50% polyethylene glycol 300 in water |
| Administration | i.p. |
| Molecular Weight | 610.59 |
| Formula | C29H27F5N2O5S |
| CAS Number | 1456632-40-8 |
| Solubility (25°C) | DMSO ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related STAT Products |
|---|
| HP590
HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). |
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. |
| HJC0123
HJC0123 is a novel STAT3 inhibitor that suppresses the fibrogenic properties of HSCs. HJC0123 reduced the phosphorylation, nuclear translocation, and transcriptional activity of STAT3. HJC0123 treatment resulted in the inhibition of HSCs proliferation at submicromolar concentrations. It decreased the expression of STAT3-regulated proteins, induced cell cycle arrest, promoted apoptosis and downregulated SOCS3. |
| ODZ10117
ODZ10117 is a small molecule inhibitor of STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells. |
| OPB-111077
OPB-111077 is a first-in-class, novel, oral inhibitor of STAT3 and mitochondrial oxidative phosphorylation (OXPHOS) with anticancer activity. OPB-111077 inhibits mitochondrial respiratory chain complex I, which leads to inhibition of energy production and activation of the AMPK-mTOR energy stress sensor pathway. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
